These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22266460)

  • 1. Better stent expansion by two-time inflation of stent balloon and its responsible mechanism.
    Iwamoto Y; Okamoto M; Hashimoto M; Fukuda Y; Iwamoto A; Iwasaki T; Kinoshita H; Kihara Y
    J Cardiol; 2012 Mar; 59(2):160-6. PubMed ID: 22266460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Underexpansion of sirolimus-eluting stents: incidence and relationship to delivery pressure.
    Cheneau E; Satler LF; Escolar E; Suddath WO; Kent KM; Weissman NJ; Waksman R; Pichard AD
    Catheter Cardiovasc Interv; 2005 Jun; 65(2):222-6. PubMed ID: 15900554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of a prolonged delivery inflation time for optimal drug-eluting stent expansion.
    Kawasaki T; Koga H; Serikawa T; Orita Y; Ikeda S; Mito T; Gotou Y; Shintani Y; Tanaka A; Tanaka H; Fukuyama T; Koga N
    Catheter Cardiovasc Interv; 2009 Feb; 73(2):205-11. PubMed ID: 19085915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of paclitaxel-eluting stent and sirolimus-eluting stent expansion at incremental delivery pressures.
    Javaid A; Chu WW; Cheneau E; Clavijo LC; Satler LF; Kent KM; Weissman NJ; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2006; 7(4):208-11. PubMed ID: 17174865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Better inflation time of stent balloon for second-generation drug-eluting stent expansion and apposition: an optical coherence tomography study.
    Ann SH; Chung JW; DE Jin C; Lee JH; Kim JM; Garg S; Shin ES
    J Interv Cardiol; 2014 Apr; 27(2):171-6. PubMed ID: 24593834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of balloon inflation time on expansion of sirolimus-eluting stent.
    Asano T; Kobayashi Y; Fukushima K; Iwata Y; Kitahara H; Ishio N; Nakayama T; Kuroda N; Komuro I
    Heart Vessels; 2009 Sep; 24(5):335-9. PubMed ID: 19784815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary stent implantation technique: prolonged inflation time maximizes stent expansion.
    Saha M; Poliacikova P; de Belder A; Holmberg S; Clarke M; Rajani R; Hildick-Smith D
    J Invasive Cardiol; 2013 Jan; 25(1):28-31. PubMed ID: 23293172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravascular ultrasound assessment of drug-eluting stent expansion.
    de Ribamar Costa J; Mintz GS; Carlier SG; Fujii K; Sano K; Kimura M; Tanaka K; Costa RA; Lui J; Na Y; Castellanos C; Biro S; Moussa I; Stone GW; Moses JW; Leon MB
    Am Heart J; 2007 Feb; 153(2):297-303. PubMed ID: 17239693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter randomized trial comparing amphilimus- with paclitaxel-eluting stents in de novo native coronary artery lesions.
    Carrié D; Berland J; Verheye S; Hauptmann KE; Vrolix M; Violini R; Dibie A; Berti S; Maupas E; Antoniucci D; Schofer J
    J Am Coll Cardiol; 2012 Apr; 59(15):1371-6. PubMed ID: 22284328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of polymer formulations on neointimal proliferation after zotarolimus-eluting stent with different polymers: insights from the RESOLUTE trial.
    Waseda K; Ako J; Yamasaki M; Koizumi T; Sakurai R; Hongo Y; Koo BK; Ormiston J; Worthley SG; Whitbourn RJ; Walters DL; Meredith IT; Fitzgerald PJ; Honda Y
    Circ Cardiovasc Interv; 2011 Jun; 4(3):248-55. PubMed ID: 21586691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-eluting stents in bifurcation lesions: to stent one branch or both?
    Assali AR; Assa HV; Ben-Dor I; Teplitsky I; Solodky A; Brosh D; Fuchs S; Kornowski R
    Catheter Cardiovasc Interv; 2006 Dec; 68(6):891-6. PubMed ID: 17086532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of Rapamycin and Paclitaxel eluting stent in patients with multi-vessel coronary disease].
    Han YL; Wang XZ; Jing QM; Wang SL; Ma YY; Luan B
    Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Feb; 34(2):123-6. PubMed ID: 16626577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-in-man study of paclitaxel-eluting stent BiOSS (Bifurcation Optimisation Stent System) dedicated for coronary bifurcation stenoses: three months results.
    Gil RJ; Vassiliev D; Michałek A; Kern A; Formuszewicz R; Dobrzycki S; Lesiak M; Wójcik J; Kardaszewicz P; Lekston A
    Kardiol Pol; 2012; 70(1):45-52. PubMed ID: 22267425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Six-month results of the NEVO Res-Elution I (NEVO RES-I) trial: a randomized, multicenter comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberté paclitaxel-eluting stent in de novo native coronary artery lesions.
    Ormiston JA; Abizaid A; Spertus J; Fajadet J; Mauri L; Schofer J; Verheye S; Dens J; Thuesen L; Dubois C; Hoffmann R; Wijns W; Fitzgerald PJ; Popma JJ; Macours N; Cebrian A; Stoll HP; Rogers C; Spaulding C;
    Circ Cardiovasc Interv; 2010 Dec; 3(6):556-64. PubMed ID: 21062998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: results from the first phase of the prospective multicentre German DES.DE registry.
    Abdel-Wahab M; Nienaber CA; Mostafa AE; Sabin G; Tebbe U; Hochadel M; Senges J; Akin I; Kuck KH; Hamm C; Richardt G;
    EuroIntervention; 2011 Jun; 7(2):201-8. PubMed ID: 21646062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Target lesion revascularisation in patients treated with a sirolimus-eluting or paclitaxel-eluting stent.
    Maeng M; Okkels Jensen L; Rasmussen K; Flensted Lassen J; Romer Krusell L; Thayssen P; Thuesen L
    Heart; 2007 Jun; 93(6):694-7. PubMed ID: 17194711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of paclitaxel elution from reservoirs with bioabsorbable polymer compared to a bare metal stent for the elective percutaneous treatment of de novo coronary stenosis: the EUROSTAR-II randomised clinical trial.
    Silber S; Gutiérrez-Chico JL; Behrens S; Witzenbichler B; Wiemer M; Hoffmann S; Slagboom T; Harald D; Suryapranata H; Nienaber C; Chevalier B; Serruys PW
    EuroIntervention; 2011 May; 7(1):64-73. PubMed ID: 21550905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
    Stone GW; Moses JW; Ellis SG; Schofer J; Dawkins KD; Morice MC; Colombo A; Schampaert E; Grube E; Kirtane AJ; Cutlip DE; Fahy M; Pocock SJ; Mehran R; Leon MB
    N Engl J Med; 2007 Mar; 356(10):998-1008. PubMed ID: 17296824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.